ArticleMolecular pharmacology2021
Berberine Represses
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Berberine in breast cancer, a multi-targeted therapeutic agent from mechanisms to clinical translation.Molecular biology reports · 2026Review
- Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities.Acta pharmaceutica Sinica. B · 2026Review
- Unveiling Berberine's Therapeutic Mechanisms Against Hepatocellular Carcinoma via Integrated Computational Biology and Machine Learning Approaches: AURKA and CDK1 as Principal Targets.International journal of molecular sciences · 2025Article
- Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma.Biology direct · 2025Article
- Berberine pharmacological properties and therapeutic potential across cancer, digestive, metabolic, cardiovascular, and neurological diseases: an update review.EXCLI journal · 2025Review
- Research Hotspots of Traditional Chinese Medicine for Liver Cancer in the Future Directions: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2025Article
- The Therapeutic Effects of Bioactive Compounds on Colorectal Cancer via PI3K/Akt/mTOR Signaling Pathway: A Critical Review.Food science & nutrition · 2024Review
- Berberine Protects against Hepatocellular Carcinoma Progression by Regulating Intrahepatic T Cell Heterogeneity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.Thoracic cancer · 2024Article
- Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target.Frontiers in oncology · 2024Review
- Targeting the mTOR Pathway in Hepatocellular Carcinoma: The Therapeutic Potential of Natural Products.Journal of inflammation research · 2024Review
- Antitumor Effect of Berberine Analogs in a Canine Mammary Tumor Cell Line and in Zebrafish Reporters via Wnt/β-Catenin and Hippo Pathways.Biomedicines · 2023Article
- Article
- Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.Cell death & disease · 2022Article
- Current Perspective of Traditional Chinese Medicines and Active Ingredients in the Therapy of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2022Review
- Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy.Frontiers in immunology · 2022Review
- Apoptosis Induction, a Sharp Edge of Berberine to Exert Anti-Cancer Effects, Focus on Breast, Lung, and Liver Cancer.Frontiers in pharmacology · 2022Review
- Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways.Journal of hepatocellular carcinoma · 2021Review
- Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting mFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Kanchan VishnoiDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Rong KeDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Karan S SainiDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Navin ViswakarmaDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Rakesh Sathish NairDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Subhasis DasDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Zhengjia ChenDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.).
Ajay RanaDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.) basrana@uic.edu.
Basabi RanaDepartment of Surgery, Division of Surgical Oncology (K.V., R.K., K.S.S., N.V., R.S.N., S.D., A.R., B.R.), University of Illinois Hospital and Health Sciences System Cancer Center (S.D., A.R., B.R.), and Division of Epidemiology and Biostatistics, School of Public Health (Z.C.), University of Illinois at Chicago, Chicago, Illinois; Biostatistics Shared Resource Core, University of Illinois Cancer Institute, Chicago, Illinois (Z.C.); and Jesse Brown VA Medical Center, Chicago, Illinois (A.R., B.R.) basrana@uic.edu.
University of Illinois Hospital & Health Sciences System · USJesse Brown VA Medical Center · USUniversity of Illinois Chicago · US
Funding
Developing Nano Technology for HER2 Directed TherapyR01CA216410 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LI, SONG, RANA, AJAY NMN · 2017 to 2021
$2.8MOncogenic MLK3-Pak1 Signaling in ER Negative Breast CancerR01CA176846 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, AJAY NMN · 2013 to 2017
$1.6MRole of beta-catenin in apoptosis resistance of hepatocellular carcinomaR01CA178063 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, BASABI · 2014 to 2018
$1.6MMechanistic Insight on the Role of Berberine and AMPK in Hepatocellular CarcinomaR03CA219764 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, BASABI · 2019 to 2020
$160kBLRD VA I01 BX002355BLRD VA I01 BX002703BLRD VA I01 BX003296NCI NIH HHS R01 CA176846NCI NIH HHS R01 CA178063NCI NIH HHS R01 CA216410NCI NIH HHS R03 CA219764
Abstract
Aberrant activation of Wnt/
Indexed as
Adaptor Proteins, Signal TransducingBerberinebeta CateninCarcinoma, HepatocellularCell Cycle ProteinsEukaryotic Initiation FactorsHEK293 CellsHep G2 CellsHumansLiver NeoplasmsProtein BiosynthesisAdaptor Proteins, Signal TransducingBerberinebeta CateninCell Cycle ProteinsEIF4EBP1 protein, humanEIF4EBP2 protein, humanEukaryotic Initiation Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.